ELderly REspiratory VIral Cohort

NCT07813481 | Not Yet Recruiting

• 2 other identifiers: APHP2505102025-A02004-45
• Study Type: observational
• Target: 1,000
• Locations: 0 countries
• Sites: N/A

Brief Summary

In addition to SarsCov2, the main viral respiratory risks are associated with influenza viruses, respiratory syncytial virus (RSV), human metapneumovirus (hMPV) parainfluenza virus (PIV), adenovirus, rhinovirus, coronavirus and others. HMPV is a respiratory virus discovered in 2001. Like RSV, it appears to be a threat in terms of morbidity and mortality in susceptible populations. Overall, viral infections can cause significant functional decline in older patients, with 67% and 25% reported to be at least temporarily housebound or bedridden, respectively. Respiratory viral infections prevent older patients from functioning and performing their daily tasks. They therefore have a significant impact on the older patients and their families. In addition, respiratory viruses are key factors in the exacerbation of chronic diseases. The aims of this study are to provide a better understanding of the role of hMPV compared to common respiratory viruses on morbimortality, risk of dependency, quality of life alteration in older inpatients.

Conditions

Influenza Viruses; Respiratory Syncytial Virus (RSV); Severe Acute Respiratory Syndrome Coronavirus 2; Human Metapneumovirus (hMPV); Parainfluenza Virus (PIV); Adenovirus; Rhinovirus; Coronavirus

Keywords

hMPV; RSV; PIV; SarsCov2; respiratory viruses; older adults; prognosis; morbidity; mortality

Outcome Measures

Primary Outcomes (1)

• Proportion of participants with death and/or organ decompensation at Day 180

  Proportion of participants who died and/or experienced at least one major comorbidity decompensation (cardiac, renal, or respiratory) by Day 180.

  From baseline Day 0 to Day 180

Secondary Outcomes (10)

• Proportion of participants who died

  From baseline Day 0 to Day 30, Day 180, Day 365

• Proportion of participants with major organ decompensation

  From baseline Day 0 to Day 30, Day 180, Day 365

• Proportion of participants with unplanned hospital readmission

  From baseline Day 0 to Day 30, Day 180, Day 365

• Proportion of participants developing a lower respiratory tract infection

  From baseline Day 0 to Day 30

• Change from baseline in functional dependency assessed by ADL and/or iADL scores

  Baseline Day 0, Day 30, Day 180, Day 365

Study Arms (1)

Older patients with respiratory viral infection

Patients aged 65 years or older hospitalized in acute medicine or geriatric wards with an acute respiratory infection and a positive nasopharyngeal PCR test for a respiratory viral pathogen.

Other: Respiratory viral infection

Interventions

Respiratory viral infection OTHER

Respiratory viral infection identified by a positive nasopharyngeal PCR test. The prognostic role of human metapneumovirus (hMPV) infection will be compared with that of other common respiratory viral infections in older hospitalized patients.

Older patients with respiratory viral infection

Eligibility Criteria

• Age: 65 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients aged \>65 years with a diagnosis of acute respiratory infection and hospitalized in acute/geriatric wards

You may qualify if:

• Patient aged 65 years or older
• Positive PCR from a nasopharyngeal swab for a respiratory viral pathogen as listed: Influenza A and B, SarsCov2, RSV, hMPV, Rhinovirus/Enterovirus, Adenovirus, Coronavirus (229E, HKU1, NL63, OC43), Parainfluenza Virus 1, 2, 3, 4.
• Hospitalized in an Acute Medicine/Geriatrics Unit
• Written informed consent from patient or his/her representative, with trusted support person, a family member or, failing that, a close friend if the person is physically unable to give his or her written consent. Patients under legal protection (guardianship, curatorship, family authorisation or future protection mandate) may be included with the consent of the legally authorised person.
• Affiliated to a social security scheme

You may not qualify if:

• Refusal to participate
• Patient deprived of liberty by a judicial or administrative decision

Sponsors & Collaborators

• Assistance Publique - Hôpitaux de Paris: lead

Biospecimen

Retention: SAMPLES WITHOUT DNA

Nasopharyngeal swab specimens collected for virological and immunological analyses.

MeSH Terms

Conditions

Adenoviridae Infections; Coronavirus Infections

Condition Hierarchy (Ancestors)

DNA Virus Infections; Virus Diseases; Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections

Central Study Contacts

Giovanna Mrs MELICA, MD, PhD

CONTACT

01 49 81 2455; giovanna.melica@aphp.fr

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 4, 2026
• First Posted: September 10, 2026
• Study Start: October 1, 2026
• Primary Completion (Estimated): April 1, 2030
• Study Completion (Estimated): October 1, 2030
• Last Updated: September 10, 2026

Record last verified: 2026-09

Data Sharing

• IPD Sharing: Will not share